SELLAS Life Sciences (NASDAQ: SLS) provided an update on the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) on Dec 29, 2025. The contract research organization reported 72 pooled events (deaths) as of Dec 26, 2025; the trial requires 80 events to trigger the event-driven final overall survival analysis. SELLAS remains fully blinded to efficacy and survival data and says this aggregate update does not affect planned statistical analyses. The company will announce when the 80th event occurs.
Additional context: the Independent Data Monitoring Committee previously recommended continuing the trial without modification.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.